OMDA

Omada Health, Inc. 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. Omada Health, Inc. (OMDA) is a digital health company providing virtual care programs for cardiometabolic conditions (diabetes, hypertension, cholesterol, weight management) and musculoskeletal (MSK) issues. The company utilizes a "Compassionate Intelligence" model combining human-led care teams with AI-driven technology. As of December 31, 2025, Omada served over 2,000 customers and had 886,000 total members enrolled in its programs. The company completed its Initial Public Offering (IPO) on June 9, 2025, raising approximately $151.6 million in net proceeds.

Key Financial Metrics

Note: The company reported positive operating cash flow of $18.3 million in 2025, compared to a use of $34.2 million in 2024.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 53% year-over-year, driven by a 52% increase in average total members and higher average fees per member. Services revenue grew 53% to $241.0 million, while hardware revenue grew 60% to $19.2 million.
• Profitability Improvement: Net loss narrowed significantly from $47.1 million in 2024 to $12.8 million in 2025. Operating loss decreased from $43.7 million to $12.0 million.
• Margin Expansion: Gross margin expanded by 5.1 percentage points to 65.7%, attributed to Care Team efficiency initiatives and the expanded use of supporting technologies.
• Debt Extinguishment: The company fully repaid its MidCap Term Facility and Revolving Facility ($31.4 million principal and accrued interest) in July 2025 using IPO proceeds, resulting in a $2.1 million loss on debt extinguishment.
• Customer Concentration: Sales from or through the top five health plan and PBM partners represented 77% of revenue in 2025 (up from 69% in 2024). Two affiliates of The Cigna Group accounted for 32% and 33% of revenue, respectively.

Guidance, Outlook, and Risks

Outlook and Strategy: Management expects to continue investing in growth, R&D, and platform enhancements. The company is expanding its GLP-1 Care Tracks and has announced a new capability to prescribe GLP-1 therapies and anti-obesity medications (AOMs) to support members. The company believes its current cash position is sufficient to fund operations for at least the next 12 months.

Material Weakness in Internal Controls: The company identified a remaining material weakness in internal control over financial reporting related to inadequate formalized processes for the financial close and reporting process. While two other weaknesses were remediated in 2025, this remaining issue resulted in adjustments to the 2025 financial statements. Management is implementing a remediation plan involving hiring technical personnel and enhancing technology infrastructure.

Key Risks:

• Customer Concentration: Heavy reliance on a limited number of channel partners (specifically Cigna affiliates) creates significant revenue risk.
• Regulatory Environment: Changes in healthcare regulations, including the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which reduced Medicaid funding but expanded telehealth access for high-deductible plans.
• Competition and Market Acceptance: The digital health market is competitive and evolving; failure to maintain member engagement or clinical outcomes could impact revenue.
• Supply Chain: Reliance on a limited number of third-party suppliers for connected devices, many manufactured in China, exposes the company to tariffs and geopolitical risks.

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of the remediation plan for the remaining material weakness in internal controls over financial reporting in future filings.
• Customer Concentration: Monitor the stability of relationships with top channel partners (Cigna affiliates), which collectively accounted for 65% of 2025 revenue.
• GLP-1 Strategy Execution: Assess the adoption rates and revenue impact of the new GLP-1 prescribing capabilities and Enhanced Care Tracks.
• Operating Cash Flow Sustainability: Confirm that the shift to positive operating cash flow ($18.3M in 2025) is sustainable as the company scales.
• Regulatory Impact: Evaluate the long-term financial impact of the OBBBA and other healthcare reforms on Medicaid and employer-sponsored coverage.